Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries

 Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries

Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries

Shots: Shots:

  • Gilead has signed non-exclusive voluntary licensing agreements with Cipla, Ferozsons, Hetero, Jubilant Lifesciences and Mylan to manufacture remdesivir for distribution in 127 countries
  • Gilead will share its manufacturing know-how with the five companies to ramp up remdesivir production with each company will be allowed to set the price for its generic version of the drug
  • The licensees will not pay royalties to Gilead until the WHO declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat COVID-19

Click here to­ read full press release/ article | Ref: Gilead | Image: PMLive

Related News: Gilead’s Veklury (remdesivir) Receives MHLW’s Approval for Patients with Severe COVID-19 in Japan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post